AlphAIAlphAI — Financial news for AI agents
SEC EDGARSEP 111 min read$CADL

Tak Paul Peter sold $3.2M of CADL

Tak Paul Peter (Chief Executive Officer) sold 280,245 shares of Candel Therapeutics, Inc. (CADL) at an average of $11.28 ($10.46–$11.50, $3.16M total) across 2 trades over 2026-09-10 to 2026-09-11 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Tak Paul Peter
Published Sep 11, 2026, 10:12 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 11, 2026, 10:17 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$CADL
Bearish
medium confidence
Mentioned
$CADL
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CADLBearishLow
01

Why it matters

The sale reduces insider ownership, which some investors view as a negative signal, though the pre‑arranged plan tempers interpretation.

02

Market read

Primary relevance is to CADL shareholders; broader market impact is negligible.

03

What to watch

CEO's 10b5‑1 plan pre‑arranged; could mask lack of confidence.

Relevance 5/10Novelty 4/10Timing: filing date 2026-09-11

Background

Form 4 filing discloses insider transactions required by SEC; provides transparency on executive holdings.

Company-level read

Ticker impact

$CADLBearishMedium confidence
Context

CEO Tak Paul Peter sold 280,245 shares for $3.16M via a 10b5‑1 plan, reducing his stake to 113,321 shares.

Expected impact

Modest downward pressure, likely 1‑2% dip if market reacts.

Evidence & confidence

Insider sale of this size by the CEO suggests possible concerns, but the amount is modest relative to market cap.

Market effects

Sector

Minimal impact on biotech sector; similar insider sales are common.

Regional

No significant regional effect.

Global

Limited to investors tracking CADL.

Counterpoint

What could challenge this read

Sale may be routine liquidity need; not necessarily bearish.

Key entities

  • Company
    Candel Therapeutics, Inc.

    Biotech firm developing therapies; ticker CADL.

  • Person
    Tak Paul Peter

    CEO and Director of Candel Therapeutics.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

CADL insider trading history →

Related articles

OCT 22
$CADLMedAI 8/10

Jefferies initiates Candel Therapeutics stock with buy rating on prostate cancer data

Jefferies initiated Candel Therapeutics (NASDAQ:CADL) with a buy rating and $25 price target, citing positive Phase III prostate cancer data. The stock trades at $8.37, with analyst targets ranging from $15 to $29. The company has a strong financial position and plans a 2026 biologics license application. Recent data showed a hazard ratio of 0.70 and 80.4% negative biopsy rate. Other analysts also reiterated buy ratings and raised price targets.

investing.com2 min
OCT 2
$CADLHighAI 8/10

H.C. Wainwright reiterates Candel Therapeutics stock rating on trial data

H.C. Wainwright reiterated a Buy rating and $23 price target for Candel Therapeutics (CADL) after positive Phase 2a trial results for non-small cell lung cancer. The stock is up 88% in a year, with analysts' targets ranging from $15 to $29. The trial showed a median overall survival of 24.5 months, higher than historical benchmarks. Several analysts have recently upgraded or initiated coverage with Buy ratings and price targets between $15 and $23.

investing.com2 min
OCT 1
$CADLMedAI 9/10

Candel Therapeutics Announces Publication of Phase 2a Trial Data that Demonstrated Prolonged Survival after Systemic Immune Reactivation by Aglatimagene Besadenovec plus Valacyclovir in Patients with Unresectable Stage III/IV NSCLC with an Inadequate Response to ICI

Candel Therapeutics (CADL) reported phase 2a trial results showing median overall survival of 24.5 months in advanced NSCLC patients with inadequate response to immune checkpoint inhibitors. The trial involved 46 patients treated with aglatimagene besadenovec plus valacyclovir. Results were published in the Journal for ImmunoTherapy of Cancer. The company is advancing a phase 3 trial (AURORA) for this treatment.

globenewswire.com3 min
SEP 30
$CADLMedAI 8/10

Candel Therapeutics Announces Integrated Clinical and Biomarker Data That Showed Durable Local and Systemic Immune Activation after Aglatimagene Besadenovec in Intermediate-Risk Localized Prostate Cancer

Candel Therapeutics (CADL) reported positive data from its phase 2 PrTK05 trial, showing durable immune activation in intermediate-risk prostate cancer patients. Aglatimagene treatment reduced recurrence risk by 41% vs. placebo. The company plans to submit a BLA in Q4 2026. Data will be presented at future scientific meetings.

globenewswire.com3 min